NASDAQ:MBIO - Mustang Bio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.98 -0.05 (-1.24 %) (As of 03/21/2019 04:00 PM ET)Previous Close$4.03Today's Range$3.90 - $4.1752-Week Range$2.18 - $11.66Volume34,071 shsAverage Volume56,407 shsMarket Capitalization$108.51 millionP/E Ratio-3.49Dividend YieldN/ABeta2.42 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma. It also develops MB-104, a CS1 CAR T, which is in Preclinical study for multiple myeloma and light chain amyloidosisy; MB-103, a human epidermal growth factor receptor 2 CAR T that is in Preclinical study to treat glioblastoma multiforme and metastatic breast cancer to brain; and MB-105, a prostate stem-cell antigen CAR T for prostate and pancreatic cancers. The company has a partnership agreement with the City of Hope National Medical Center and Fred Hutchinson Cancer Research Center to develop proprietary CAR T therapies across various cancers. It also holds a license agreement with Harvard University; and a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc. Receive MBIO News and Ratings via Email Sign-up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MBIO Previous Symbol CUSIPN/A CIK1680048 Webwww.mustangbio.com Phone781-652-4500Debt Debt-to-Equity RatioN/A Current Ratio6.25 Quick Ratio10.33Price-To-Earnings Trailing P/E Ratio-3.49 Forward P/E Ratio-3.46 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book1.75Profitability EPS (Most Recent Fiscal Year)($1.14) Net Income$-31,280,000.00 Net MarginsN/A Return on Equity-65.02% Return on Assets-58.68%Miscellaneous EmployeesN/A Outstanding Shares27,263,000Market Cap$108.51 million Next Earnings Date5/13/2019 (Estimated) OptionableOptionable Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions What is Mustang Bio's stock symbol? Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO." How were Mustang Bio's earnings last quarter? Mustang Bio Inc (NASDAQ:MBIO) posted its quarterly earnings data on Monday, March, 18th. The company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.17. View Mustang Bio's Earnings History. When is Mustang Bio's next earnings date? Mustang Bio is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for Mustang Bio. What price target have analysts set for MBIO? 1 brokers have issued twelve-month target prices for Mustang Bio's stock. Their forecasts range from $18.00 to $18.00. On average, they expect Mustang Bio's stock price to reach $18.00 in the next year. This suggests a possible upside of 352.3% from the stock's current price. View Analyst Price Targets for Mustang Bio. What is the consensus analysts' recommendation for Mustang Bio? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mustang Bio. Has Mustang Bio been receiving favorable news coverage? Headlines about MBIO stock have been trending negative on Thursday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mustang Bio earned a news impact score of -2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Who are some of Mustang Bio's key competitors? Some companies that are related to Mustang Bio include Innate Pharma (IPHYF), Rigel Pharmaceuticals (RIGL), Theratechnologies (THERF), Achillion Pharmaceuticals (ACHN), MannKind (MNKD), Catalyst Pharmaceuticals (CPRX), Stemline Therapeutics (STML), Concert Pharmaceuticals (CNCE), OvaScience (OVAS), XBiotech (XBIT), OptiNose (OPTN), Beyondspring (BYSI), Progenics Pharmaceuticals (PGNX), Aptorum Group (APM) and Abeona Therapeutics (ABEO). What other stocks do shareholders of Mustang Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include Portola Pharmaceuticals (PTLA), Corbus Pharmaceuticals (CRBP), Amicus Therapeutics (FOLD), Protalix Biotherapeutics (PLX), Axsome Therapeutics (AXSM), Sorrento Therapeutics (SRNE), Trevena (TRVN), Viking Therapeutics (VKTX), Exelixis (EXEL) and Gemphire Therapeutics (GEMP). Who are Mustang Bio's key executives? Mustang Bio's management team includes the folowing people: Mr. Michael S. Weiss, Exec. Chairman (Age 53)Dr. Manuel Litchman, Pres, CEO & Director (Age 65)Mr. David Jay Horin CPA, Interim Chief Financial Officer (Age 51)Mr. Brian K. Achenbach, VP of Fin. & Corp. Controller (Age 54)Dr. Knut Niss, Chief Technology Officer Who are Mustang Bio's major shareholders? Mustang Bio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.03%), Geode Capital Management LLC (0.62%), Geode Capital Management LLC (0.62%), National Asset Management Inc. (0.30%), Bank of New York Mellon Corp (0.20%) and Fenimore Asset Management Inc. (0.14%). View Institutional Ownership Trends for Mustang Bio. Which institutional investors are buying Mustang Bio stock? MBIO stock was acquired by a variety of institutional investors in the last quarter, including Fenimore Asset Management Inc., SG Americas Securities LLC, Bank of New York Mellon Corp, National Asset Management Inc., Geode Capital Management LLC, Geode Capital Management LLC, Rhumbline Advisers and BlackRock Inc.. View Insider Buying and Selling for Mustang Bio. How do I buy shares of Mustang Bio? Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mustang Bio's stock price today? One share of MBIO stock can currently be purchased for approximately $3.98. How big of a company is Mustang Bio? Mustang Bio has a market capitalization of $108.51 million. The company earns $-31,280,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. What is Mustang Bio's official website? The official website for Mustang Bio is http://www.mustangbio.com. How can I contact Mustang Bio? Mustang Bio's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected] MarketBeat Community Rating for Mustang Bio (NASDAQ MBIO)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 85 (Vote Outperform)Underperform Votes: 108 (Vote Underperform)Total Votes: 193MarketBeat's community ratings are surveys of what our community members think about Mustang Bio and other stocks. Vote "Outperform" if you believe MBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?